Join
Live feed
·
PRReleasevia Quantisnow
Alto Neuroscience Inc. logo

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

ByQuantisnow·Wall Street's wire, on your screen.
ANRO· Alto Neuroscience Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANRO (Alto Neuroscience Inc.) and more on Quantisnow.

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway | Quantisnow